#USA #New York #Class Action #Securities Fraud #Capricor Therapeutics

Capricor Therapeutics Faces Class Action Lawsuit Over Alleged Securities Fraud

In a significant development, Capricor Therapeutics, Inc. is currently facing a class action lawsuit as a consequence of alleged securities fraud. This situation has caught the attention of both investors and legal experts, highlighting the importance of transparency in the biotech sector. The law firm Levi & Korsinsky, LLP has formally notified investors regarding this crucial legal matter.

Class Action Details

The lawsuit encompasses claims of securities fraud affecting Capricor investors between October 9, 2024, and July 10, 2025. Those who suffered losses during this period are encouraged to reach out to Levi & Korsinsky as they seek to recover damages on behalf of affected investors. Interested parties should act quickly, as the deadline for filing is set for September 15, 2025.

The complaint alleges that Capricor misrepresented essential information about its lead therapy candidate, deramiocel, which is aimed at treating cardiomyopathy related to Duchenne muscular dystrophy (DMD). Investors received overwhelmingly optimistic statements from the company regarding the approval of a Biologics License Application (BLA) from the U.S. Food and Drug Administration (FDA). However, these claims were reportedly paired with misleading information and omissions related to the safety and efficacy of deramiocel, especially in light of the trial data from the Phase 2 HOPE-2 study.

On July 11, 2025, Capricor released a press statement indicating that it had received a Complete Response Letter (CRL) from the FDA, which denied the BLA due to lack of substantial evidence demonstrating effectiveness alongside concerns over manufacturing processes. Following the release of this critical information, Capricor's stock plunged from $11.40 per share to $7.64, prompting concerns about the company’s financial health and credibility moving forward.

What Investors Should Do

For those investors who incurred losses during the specified timeframe, the opportunity to take legal action is narrowing. By reaching out to the law firm Levi & Korsinsky, investors can seek to establish their position within the lawsuit and potentially recover lost funds without incurring any upfront costs or fees. It is noteworthy that participation does not require one to serve as the lead plaintiff to share in any possible recovery.

Levi & Korsinsky is recognized for its significant track record of assisting shareholders in complex securities litigation, having secured hundreds of millions of dollars for clients over the last two decades. With a team consisting of over 70 experienced professionals, they stand ready to aid investors in navigating this challenging landscape.

Continued Commitment to Shareholder Rights

Joseph E. Levi, Esq. and Ed Korsinsky, Esq., leading figures at the firm, have reaffirmed their commitment to protecting shareholder interests. Their extensive experience in this area places them at a strategic advantage in advocating for investors potentially impacted by the alleged misconduct of Capricor.

If you are an investor in Capricor Therapeutics and feel you have been wronged, do not hesitate to reach out to Levi & Korsinsky for an assessment of your situation and guidance on how best to proceed.

You can contact the firm via email at [email protected] or by phone at (212) 363-7500. Act now to safeguard your rights as a shareholder, as the clock is ticking towards the filing deadline. Make sure that your voice is heard and that you take part in the judicial process seeking justice and compensation for your investment losses.

For more comprehensive information, including the opportunity to submit your claim, visit their official page at Levi & Korsinsky's website.

Conclusion:

The Capricor Therapeutics situation underscores the critical importance of transparency and accountability within the biotechnology sector. It is vital that investors remain vigilant and proactive in safeguarding their interests, particularly in light of such serious allegations as those currently facing the company.